Navigation Links
Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
Date:12/11/2012

medicines and solutions in five distinct therapeutic areas: Neuroscience, Oncology, Immunology, Infectious Diseases and Vaccines, and Cardiovascular and Metabolism. For more information about Janssen Research & Development, LLC visit www.janssenrnd.com.

Janssen Research & Development is part of the Janssen Pharmaceutical Companies of Johnson & Johnson.  Driven by our commitment to patients, we work together to bring innovative ideas, products, services and solutions to address serious unmet medical needs around the world.

About Janssen Biotech, Inc.

Janssen Biotech, Inc. redefines the standard of care in immunology, oncology, urology and nephrology.  Built upon a rich legacy of innovative firsts, Janssen Biotech has delivered on the promise of new treatments and ways to improve the health of individuals with serious disease. Beyond its innovative medicines, Janssen Biotech is at the forefront of developing education and public policy initiatives to ensure patients and their families, caregivers, advocates and health care professionals have access to the latest treatment information, support services and quality care. For more information on Janssen Biotech, Inc. or its products, visit www.janssenbiotech.com.

Janssen Biotech, Inc. is one of the Janssen Pharmaceutical Companies of Johnson & Johnson, dedicated to addressing and solving some of the most important unmet medical needs in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we work together to bring innovative ideas, products, services and solutions to people throughout the world.  Follow us on Twitter at www.twitter.com/JanssenUS.

(This press release contains "forward-looking statements" as defined in the Pr
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
2. Six-Year Follow-Up Data for SPRYCEL®? (dasatinib) 100 mg Once Daily Demonstrates 71 Percent Overall Survival in Patients with Chronic-Phase Chronic Myeloid Leukaemia Resistant or Intolerant to Imatinib
3. Landauer, Inc. Reports Fiscal 2012 Fourth Quarter And Year End Results
4. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
5. IRIDEX Corporation Announces Preliminary Results of its Tender Offer
6. American Pacific to Release Financial Results and Hold Fiscal 2012 Year-End and Fourth Quarter Investor Teleconference
7. PNAS Publishes Preclinical Results of EntreMeds 2ME2 for Multiple Sclerosis
8. The Female Health Company Reports Record Fourth Quarter and FY2012 Operating Results
9. ObeTherapy Announces the Publication of Results Obtained with one of its Lead Compounds on a New Target for the Treatment of Obesity and Type II Diabetes
10. InspireMD to Discuss MGuard(TM) and the MASTER Randomized Trial Results at the ICI 2012 Meeting
11. Landauer, Inc. Sets Date And Time For Announcement Of Fiscal Fourth Quarter And Full Year 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... , July 6, 2015  OrthoSpace Ltd. ("OrthoSpace" ... first three patients in its US Investigational Device ... 184 patient randomized, single blinded control study that ... conventional repair or partial repair for the treatment ... InSpace is currently commercially available outside of ...
(Date:7/6/2015)... PARIS , July 6, 2015 ... inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy ... Japan,s Ministry of Health, ... Confocal Laser Endomicroscopy solution, the AQ-Flex 19 miniprobe. ... Cellvizio AQ -Flex™ 19 miniprobe is comprised of ...
(Date:7/6/2015)... , June 29, 2015 ... of the "Pharmaceutical Packaging Market in North America ... pharmaceutical packaging market in North America ... the period 2014-2019. International regulations regarding ... drug manufacturers, which in turn fuels adoption of sustainable ...
Breaking Medicine Technology:OrthoSpace Enrolls First Patients in US IDE Study 2Mauna Kea Technologies Receives Regulatory Approval for the AQ-Flex 19 Miniprobe in Japan 2Mauna Kea Technologies Receives Regulatory Approval for the AQ-Flex 19 Miniprobe in Japan 3North American Pharmaceutical Packaging Market 2015-2019 with Amcor, Bemis Healthcare Packaging, MeadWestvaco, Owens-Illinois & West Pharmaceutical Services Dominating 2North American Pharmaceutical Packaging Market 2015-2019 with Amcor, Bemis Healthcare Packaging, MeadWestvaco, Owens-Illinois & West Pharmaceutical Services Dominating 3
... SOUTH SAN FRANCISCO, Calif., Dec. 7, 2011 Rigel ... that Raul Rodriguez, the company,s president and chief operating ... the Oppenheimer 22nd Annual Healthcare Conference in New York ... (Logo: http://photos.prnewswire.com/prnh/20030226/RIGLLOGO ) ...
... (NYSE AMEX: IBIO ) today announced that Jules ... a Managing Director of the Company for at least the ... development activity.  Mr. Musing, formerly a Senior Executive at Johnson ... 2011.  In the course of his career in the Pharmaceutical ...
Cached Medicine Technology:Jules Musing to Lead Business Development Effort 2Jules Musing to Lead Business Development Effort 3
(Date:7/6/2015)... ... ... TapGlance ” was featured on NewsWatch as part of its monthly AppWatch, which takes ... and Windows. Joe Toohey, the host of AppWatch and technology expert, conducted the app ... rooms will look like before they even start renovating.. , Whether a person is ...
(Date:7/6/2015)... ... July 06, 2015 , ... ... Medical Spa industries, announces the return of its complimentary educational webinar series ... aesthetic medical business leaders creates success for their clients through targeted marketing, sales, ...
(Date:7/6/2015)... ... 2015 , ... Understanding the new ICD-10 requirements is crucial ... transition. ADVOCATE, the only 100% radiology, revenue cycle management company in the nation, ... ten tips are timely and relevant guidelines to help radiology practices avoid coding ...
(Date:7/6/2015)... ... July 06, 2015 , ... Health care systems and ... of the medical field to access and use this “Big Data” to improve health ... and Chief Executive Officer of the Mount Sinai Health System in New York City. ...
(Date:7/6/2015)... Atlanta, Georgia (PRWEB) , ... July 06, 2015 ... ... University has received nearly $400,000 in grant funds to support a three-year effort ... Atlanta. , The work will be conducted in partnership with the Morehouse School ...
Breaking Medicine News(10 mins):Health News:Create a Space with TapGlance, a Revolutionary Interior Design Application 2Health News:Acara Partners Announces Complimentary Educational Webinar Series for Cosmetic Medical Practices and MedSpas 2Health News:Acara Partners Announces Complimentary Educational Webinar Series for Cosmetic Medical Practices and MedSpas 3Health News:ADVOCATE Takes the Lead to Ensure ICD-10 Success: “Top 10 Tips for ICD-10” 2Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 2Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 3Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 4Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 5Health News:Georgia State, Morehouse Partner To Tackle Diabetes, Heart Disease In Atlanta’s Minority Communities 2
... (HealthDay News) -- For newly diagnosed cancer patients, appointments with ... those with private health insurance, according to U.S. researchers. ... assistants posing as new cancer patients were unable to obtain ... The findings, from a team at the Perelman School of ...
... data presented at The American Society of Clinical Oncology ... tumor vaccine HSPPC-96 for treating recurrent gliobastoma (GBM) has ... to three times more than the current median survival ... Hospitals Case Medical Center, University of California, San Francisco ...
... epidemic, a once-rare form of cancer known as Kaposi,s sarcoma ... was best illustrated by Tom Hanks, who portrayed a gay ... co-workers in the 1993 movie "Philadelphia." A few years ... searching for a postdoctoral position. He found one, in Philadelphia, ...
... , THURSDAY, June 2 (HealthDay News) -- They are ... new research reveals that used faceshields are more likely to ... equipment managers, conducted by Ohio State University, also found that ... replacement policy in place for used or damaged shields. ...
... , THURSDAY, June 2 (HealthDay News) -- Noisy operating rooms ... infections, new study findings suggest. In the report, ... of Surgery , the Swiss researchers also said these surgical ... hospital stays. "SSIs lead to patients spending up to ...
... than 70 with glioblastoma, the most common and aggressive ... for those living in poorer areas and older than ... presented at the American Society of Clinical Oncology annual ... on Saturday, June 4. ( ABSTRACT #6089 ). ...
Cached Medicine News:Health News:U.S. Cancer Patients Face Barriers to Care, Study Finds 2Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 2Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 3Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 4Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 5Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 6Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 7Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 8Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 9Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 10Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 11Health News:Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times 12Health News:FSU scientist leads research on AIDS-related cancer 2Health News:FSU scientist leads research on AIDS-related cancer 3Health News:Used Football Faceshields May Break on Impact 2Health News:Noisy ORs Linked to Raised Risk of Surgical Site Infection 2Health News:ASCO: Glioblastoma in the 21st century: Wealthier patients living longer than poorer patients 2
... with concave seats and large backrests ... like seats, backrests, armrests, and casters ... Series for top performance in a ... laboratory, clean room, static control, health ...
... ergonomic chairs with concave seats and ... Select options like seats, backrests, armrests, ... the BE Series for top performance ... industry, education, laboratory, clean room, static ...
... concave seats and large backrests with lumbar ... armrests, and casters and glides. • Choose ... a variety of environments including: industry, education, ... and office. • With cast aluminum base ...
... concave seats and large backrests with lumbar ... armrests, and casters and glides. • Choose ... a variety of environments including: industry, education, ... and office. • With cast aluminum base ...
Medicine Products: